2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects. On 23rd April 2024, the FDA approved LUTATHERA (also known as lutetium Lu 177 dotatate) for the treatment of pediatric patients of 12 years and older with somatostatin receptor (SSTR)-pos...
Find MoreAB-1005 represents a pioneering gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene directly into the brain. This innovative technique allows for precise and sustained expression of GDNF, offering promising ther...
Find MoreLIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope, offering convenient alternatives to existing device-based products, for managing acute repetitive seizure emergencies in young patients. LIBERVANT utilizes "fast-melt strips" for "buccal delivery of...
Find MoreABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's disease by providing continuous subcutaneous delivery of carbidopa and levodopa prodrugs, aiming to address motor fluctuations more effectively than oral medication. Leveraging its small molecule...
Find MoreDAXXIFY (daxibotulinumtoxinA) injection represents a novel approach to treating cervical dystonia in adults and addressing moderate to severe glabellar lines associated with muscle activity, offering potential relief and aesthetic enhancement for patients. Powered by Revance's innovative Peptide Exchange Techno...
Find MoreInhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson’s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression. Risvo...
Find MoreOcrelizumab proves superior to first-line therapies in early RRMS, promoting better outcomes. Long-term data spanning a decade validate Ocrelizumab’s sustained efficacy and safety across MS stages, enhancing patient management. At the 2024 American Academy of Neurology conference, significant findings were ...
Find MoreDAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who experience challenges with sleep onset and/or maintenance. It has received approval for insomnia treatment in over 15 countries, such as Japan, the United States, Canada, Australia, and various Asian nati...
Find MoreBiohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by providing innovative therapeutic choices with improved tolerability for epilepsy patients. BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, presents a promising avenue, navigatin...
Find MoreFenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to treat relapsing and primary progressive MS. Fenebrutinib treatment resulted in decreased new lesion activity and enhanced penetration into the cerebrospinal fluid (CSF) in multiple sclerosis (MS...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.